drugset / Trial / NCT01647542

Study to Evaluate the Efficacy and Safety of Daily Oral TAK-875 25 and 50mg in Asia Pacific Adults With Type 2 Diabetes

NCT01647542

Phase 3 Terminated 393 enrolled Takeda
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The purpose of this study is to evaluate the efficacy and safety of TAK-875 in Asia Pacific adults with type 2 diabetes mellitus (T2DM).

Timeline

Start
2012-10
Primary completion
2014-02
Completion
2014-03

Drugs

EvaluationDrugModalityDoseRoute
Subject Fasiglifam Small molecule 25 mg Oral
Subject Fasiglifam Small molecule 50 mg Oral